Outlook
For the remainder of 2017, the Company expects:
• Continued growth in revenues from sales of RUCONEST, mainly driven by the US operations.
• Achievement of positive quarterly Operating Results in the course of the year.
• Continued investment in the production of RUCONEST® in order to ensure continuity of
supply to the growing markets in the US, Europe and the rest of the world.
• Investment in the approval or further clinical trial program for RUCONEST® in prophylaxis of
HAE and the development of a small IV version and new intramuscular and subcutaneous
versions of RUCONEST®.
• We will also continue to invest carefully in the new pipeline programs in Pompe disease and
Fabry’s disease, and other new development opportunities and assets as these occur.
• Increasing marketing activity where this can be profitable for Pharming, such as in our
current major territories of the United States, Austria, France, Germany, the United
Kingdom and the Netherlands.
• We will continue to support all our teams and marketing partners in order to enable the
maximization of the sales and distribution potential of RUCONEST® for patients in all
territories, as we continue to believe that RUCONEST® represents the fastest, most
effective, most reliable and safest therapy option available to HAE patients.
No further financial guidance for 2017 is provided.
Although the requirement to produce quarterly reports has been discontinued under the new EU
Transparency Directive and the Amended Transparency Directive Implementation Act, Pharming
intends to continue to provide quarterly operating and financial reports on a voluntary basis.
The Board of Management
Sijmen de Vries, CEO
Bruno Giannetti, COO
Robin Wright, CFO